Gustave Roussy Cancer Campus-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

  1. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    Blood, Vol. 141, Núm. 2, pp. 156-167

2012

  1. Phase i studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

    Investigational New Drugs, Vol. 30, Núm. 3, pp. 1121-1131

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998